Smrithi Hariharaputran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Smrithi Hariharaputran has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Tanoto Tan
Duke-NUS Medical School
1 shared publication - Antonio Bertoletti
Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore
1 shared publication - Apostolos Koffas
Immunobiology, Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
1 shared publication - Elisabetta Degasperi
Division of Gastroenterology and Hepatology Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
1 shared publication - Floriana Facchetti
Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
1 shared publication Lung-Yi Mak
Barts Liver Center, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
1 shared publication
Latest Publications
- Open Access
Heterogeneous T cell responses across Hepatitis B virus clinical phases revealed by rapid whole-blood HBV T cell analysis
Background & Aims Virus-specific T cells are crucial for controlling viral replication and disease progression in chronic hepatitis B (CHB). Nevertheless, due to the complexity of their analysis, CHB management relies exclusively on virological and biochemical markers. We aimed to develop a point-of-care immunological test, the HBV-cytokine release assay (HBV-CRA), designed to measure multiple cytokines in whole blood after HBV-peptide pool stimulation. Methods We first assessed the assay’s sensitivity by spiking whole blood with engineered HBV-specific T cells. Next, the performance of HBV-CRA was compared to ex vivo IFN-γ ELISpot assays in terms of sensitivity and consistency. We then applied the assay in a cross-sectional study of 235 CHB patients and longitudinally in acute HBV patients during HBsAg sero-clearance. Results The HBV-CRA detected cytokine secretion in response to peptide pools in approximately 80% of CHB patients. A profile of high IL-2 and IFN-γ after Core peptide stimulation was significantly associated with HBsAg clearance in acute HBV. The assay also revealed variability in cytokine levels and responses to different HBV proteins, even within the same clinical phase of CHB. Unsupervised clustering identified distinct HBV-specific immune patterns that did not segregate by clinical and virological categories. Notably, the assay revealed that NUC treatment impacted the functional profile of HBV-specific T cell responses. Conclusions The HBV-CRA is a rapid, easy-to-use assay that detects immune profiles linked to HBsAg clearance and distinguishes CHB patients based on antiviral T cell function. This capability to stratify patients within similar clinical phases offers a novel biomarker for host-viral interactions and could guide the selection of novel immunotherapies.
Open AccessHeterogeneous T cell responses across Hepatitis B virus clinical phases revealed by rapid whole-blood HBV T cell analysis
Background & Aims Virus-specific T cells are crucial for controlling viral replication and disease progression in chronic hepatitis B (CHB). Nevertheless, due to the complexity of their analysis, CHB management relies exclusively on virological and biochemical markers. We aimed to develop a point-of-care immunological test, the HBV-cytokine release assay (HBV-CRA), designed to measure multiple cytokines in whole blood after HBV-peptide pool stimulation. Methods We first assessed the assay’s sensitivity by spiking whole blood with engineered HBV-specific T cells. Next, the performance of HBV-CRA was compared to ex vivo IFN-γ ELISpot assays in terms of sensitivity and consistency. We then applied the assay in a cross-sectional study of 235 CHB patients and longitudinally in acute HBV patients during HBsAg sero-clearance. Results The HBV-CRA detected cytokine secretion in response to peptide pools in approximately 80% of CHB patients. A profile of high IL-2 and IFN-γ after Core peptide stimulation was significantly associated with HBsAg clearance in acute HBV. The assay also revealed variability in cytokine levels and responses to different HBV proteins, even within the same clinical phase of CHB. Unsupervised clustering identified distinct HBV-specific immune patterns that did not segregate by clinical and virological categories. Notably, the assay revealed that NUC treatment impacted the functional profile of HBV-specific T cell responses. Conclusions The HBV-CRA is a rapid, easy-to-use assay that detects immune profiles linked to HBsAg clearance and distinguishes CHB patients based on antiviral T cell function. This capability to stratify patients within similar clinical phases offers a novel biomarker for host-viral interactions and could guide the selection of novel immunotherapies.